Biodiversidade

Disponível somente no TrabalhosFeitos
  • Páginas : 130 (32311 palavras )
  • Download(s) : 0
  • Publicado : 5 de outubro de 2011
Ler documento completo
Amostra do texto
Lenalidomide Protocol CC-5013-MM-020/IFM 07-01

Celgene Corporation

COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE [include if applicable]

Signature of Coordinating Principal Investigator

dd/mm/yy

Printed Name of Coordinating Principal Investigator and Title Site Number________ By my signature, I agree to supervise and oversee the conduct of this study and to ensure its conductis in compliance with the protocol, informed consent, IRB/IEC procedures, instructions from Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices guidelines, and the applicable parts of the United States Code of Federal Regulations and local regulations governing the conduct of clinical studies.

Confidential and Proprietary

2

Amendment #1: 07 November 2008 Lenalidomide Protocol CC-5013-MM-020/IFM 07-01

Celgene Corporation

SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE

Signature of Site Principal Investigator

dd/mm/yy

Printed Name of Site Principal Investigator and Title Site Number________ By my signature, I agree to personally supervise the conduct of this study at my study site and to ensure its conduct is in compliance with theprotocol, informed consent, IRB/EC procedures, instructions from Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices guidelines, and the applicable parts of the United States Code of Federal Regulations and local regulations governing the conduct of clinical studies.

Confidential and Proprietary

3

Amendment #1: 07 November 2008

Lenalidomide ProtocolCC-5013-MM-020/IFM 07-01

Celgene Corporation

1.
Table 1:

STUDY CONTACT INFORMATION
Celgene Emergency Contact Information
Name Address and Telephone Number Role in Study

Global Study Manager

Elvira Klissourska, PhD

Celgene International Sarl Route de Perreux 1 2017 – Boudry Switzerland Tel: + 41 32 7298432 Mobile: +41 795709820 E-mail: eklissourska@celgene.com Celgene International SarlRoute de Perreux 1 2017 – Boudry Switzerland Tel: + 41 32 7298738 E-mail: hniederbroeker@celgene.com Celgene Corporation 86 Morris Avenue Summit, NJ 07901 USA Tel: 908-673-2363 Fax: 908-673-2775 E-mail: lreynolds@celgene.com Celgene Corporation 86 Morris Avenue Summit, NJ 07901 USA Tel: 908-673-9749 E-mail: rknight@celgene.com

Study Manager Europe, Australia, New Zealand

Heike Niederbröker,MSc, PhD

Study Manager North America

Linda Reynolds

Responsible Clinical Research Physician

Robert Knight, MD

Confidential and Proprietary

4

Amendment #1: 07 November 2008

Lenalidomide Protocol CC-5013-MM-020/IFM 07-01 Table 1: Celgene Emergency Contact Information (Continued)
Name

Celgene Corporation

Role in Study

Address and Telephone Number

InternationalDrug Safety Contact
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse Event Report Form Completion Guidelines.

Clinical Trial Safety

Celgene International Sàrl Route de Perreux 1 2017- Boudry Neuchatel Switzerland Tel: + 41 327 298 776 Fax: + 41 327 298 709 drugsafetyeurope@celgene.com Celgene Corporation 86 Morris Avenue Summit, NJ 07901 USA Tel:908-673-9667 Fax: 908-673-9115
drugsafety@celgene.com

North America Drug Safety Contact

Clinical Trial Safety

24-Hour emergency contact

Call Centre

Tel: + 49 6103 904 1953

Name of central clinical laboratory(ies) and other medical and/or technical department(s) and /or institutions 1. ICON Clinical Research Inc. Granite Towers 13135 Dairy Ashford, Suite 150 Sugarland, TX 77478USA Phone: 1 (281) 295-4800 Fax: 1 (281) 242-4890 2. Quest Diagnostics Clinical Trials Unit B1, Parkway West Industrial Estate Cranford Lane Heston, Middlesex TW5 9QA - United Kingdom Phone: +44 (0) 208 377 3300 3. Quest Diagnostics Clinical Trials 7600 Tyrone Avenue Suite 2S Van Nuys, CA 91405 U.S.A.

Confidential and Proprietary

5

Amendment #1: 07 November 2008

Lenalidomide Protocol...
tracking img